Equities research analysts at StockNews.com started coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Get Free Report) in a report issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
RedHill Biopharma Price Performance
NASDAQ RDHL opened at $2.17 on Tuesday. The stock’s fifty day moving average price is $3.13 and its 200 day moving average price is $5.69. RedHill Biopharma has a 1 year low of $1.72 and a 1 year high of $20.28.
Institutional Trading of RedHill Biopharma
A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC purchased a new stake in RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned 0.40% of RedHill Biopharma at the end of the most recent quarter. 7.20% of the stock is currently owned by institutional investors.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Read More
- Five stocks we like better than RedHill Biopharma
- Short Selling – The Pros and Cons
- AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock
- Dividend Payout Ratio Calculator
- Why Call Option Traders Are Targeting This Dividend ETF Now
- There Are Different Types of Stock To Invest In
- Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
